Patents Assigned to Merck
  • Electrooptical liquid crystal system
    Patent number: 6682661
    Abstract: To improve switching times, especially at low temperatures, one or more reactive liquid crystalline compounds is added to a liquid crystal mixture used in an electroptical system. The electroptical system comprises a PDLC film comprising a liquid crystal mixture forming micro-droplets in an optically isotropic, transparent polymer matrix between 2 electrode layers. The liquid crystal mixture comprises one or more compounds of the formula I wherein R, A1, A2, Z1, Z2, X1, X2, Q, Y and n are as defined herein.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 27, 2004
    Assignee: Merck Patent Gesellschaft
    Inventors: David Coates, Owain Llyr Parri, Simon Greenfield, Martin David Tillin, Mark John Goulding, Patrick Nolan
  • Recovery of isoquercetin from bioflavanoid pastes
    Patent number: 6683164
    Abstract: The invention relates to a method for recovering high-purity isoquerectin from bioflavonoid pastes, that is from mother-liquor residues which are produced during the recovery of flavonoids, by extraction with a solvent mixture of methyl acetate and water.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: January 27, 2004
    Assignee: Merck Patent GmbH
    Inventors: Herwig Buchholz, Michael Jungnitz, Michael Grund, Ralf Rosskopf, Hartmut Härtner
  • Mouse growth hormone secretagogue receptor
    Patent number: 6682908
    Abstract: A mouse growth hormone secretagogue receptor has been isolated, cloned and sequenced. This receptor is characteristic of the G-protein family of receptors. Mouse growth hormone secretagogue receptors may be used to screen and identify compoumds which bind to the mouse growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and those recovering from hip fracture and osteoporosis. Targeted disruption of the mouse GHS-R gene may prove useful in elucidation of the mechanism of action and role of the growth hormone secretagogues in human and animal physiology.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: January 27, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Roy G. Smith, Leonardus H. T. Van der Ploeg, Andrew D. Howard, Hui Zheng, Karen Kulju McKee, Michael M. Jiang
  • Colored inscription and marking of plastics and surface coatings
    Publication number: 20040013969
    Abstract: The present invention relates to the colored inscription or marking of plastics and surface coatings, including powder coatings, in which a colorant is transferred into the plastic or surface coating by laser radiation with the aid of a laser light-absorbent substance.
    Type: Application
    Filed: July 26, 2002
    Publication date: January 22, 2004
    Applicant: Merck Patent GmbH
    Inventors: Reiner Delp, Matthias Kuntz
  • Body pigment and process for preparaing the same
    Publication number: 20040011253
    Abstract: A body pigment with a good skin feel for cosmetics is provided which has an appropriate crumbling property and combines slipping property and adhesiveness without compromising oil absorption. The body pigment is comprised of a metallic compound and has a structure in which leaf-shaped flakes are combined and/or intersected.
    Type: Application
    Filed: March 11, 2003
    Publication date: January 22, 2004
    Applicant: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventor: Tamio Noguchi
  • Liquid-crystalline medium
    Publication number: 20040011996
    Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of compounds of negative dielectric anisotropy comprising one or more polymerizable compounds, and to the use thereof for electro-optical purposes, and to displays containing this medium.
    Type: Application
    Filed: July 3, 2003
    Publication date: January 22, 2004
    Applicant: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Dagmar Klement, Matthias Bremer
  • Anti-hypercholesterolemic drug combination
    Patent number: 6680340
    Abstract: This invention provides a drug combination comprised of a thyroid hormone receptor beta agonist with a fibrate in therapeutically effective amounts, which is useful for reducing cholesterol synthesis, lowering plasma cholesterol levels and lowering plasma triglyceride levels.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: January 20, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Kang Cheng, Samuel D. Wright, Tsuei-Ju Wu
  • Supply system for chemicals and its use
    Patent number: 6679764
    Abstract: The present invention relates to a novel supply system for chemicals which permits the preparation of solid-containing suspensions, which are required, inter alia, for polishing wafers or in semiconductor production, directly at the point of use.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: January 20, 2004
    Assignee: Merck Patent GmbH
    Inventors: Ulrich Finkenzeller, Claus Dusemund, Thomas Schwortschik
  • Phenylcyclohexanes and a liquid-crystalline medium
    Patent number: 6677002
    Abstract: Novel phenylcyclohexanes of the formula I: in which n is 0 to 7, Q1 and Q2 are H, or one of these radicals is alternatively CH3, r is 0, 1, 2, 3, 4 or 5, A is trans-1,4-cyclohexylene, 1,4-phenylene, 3-fluoro-1,4-phenylene or a single bond, X is F, Cl, —CF3, —CN, —OCF3 or —OCHF2, and Y and Z are each, independently of one another, H or F, with the proviso that, in the case where A is a single bond, Q1═Q2═H and simultaneously X═CN, Y and/or Z are F.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: January 13, 2004
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Andreas Wächtler, Reinhard Hittich, Eike Poetsch, Herbert Plach, David Coates, Bernhard Rieger, Joachim Krause
  • 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
    Patent number: 6677351
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: January 13, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
  • Mono-, oligo- and poly-4-fluorothiophenes and their use as charge transport materials
    Patent number: 6676857
    Abstract: Mono-, oligo- and polymers comprising one or more identical or different recurring units of formula I —[(Y)a—(D)b—(Z)c]—  I wherein D is a 3-substituted-4-fluorothiophene group of formula II, wherein Y, Z, R1, a, b and c have the meanings defined herein, are useful as semiconductors or charge transport materials.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: January 13, 2004
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Martin Heeney, Louise Farrand, Mark Giles, Marcus Thompson, Steven Tierney, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • Polymer beads
    Patent number: 6677042
    Abstract: The invention relates to polymer beads comprising an anisotropic polymer material with helically twisted structure, to their use in reflective films, spraying or printing inks or as pigments, for optical or electrooptical, decorative or security applications, to a reflective film comprising one or more polymer beads in a transmissive binder, and to a security marking or security device comprising one or more polymer beads or comprising a reflective film.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: January 13, 2004
    Assignee: Merck Patent GmbH
    Inventors: Matthias Kuntz, David Coates, Simon Greenfield, John Patrick
  • Pb-Bi-Sr-Ca-Cu-oxide powder mix with enhanced reactivity and process for its manufacture
    Patent number: 6677278
    Abstract: An Oxide Precursor Powder from the Pb—Bi—Sr—Ca—Cu—O 2223 System can be produced by heat treating powder, produced using the Spray Pyrolysis Process as described in: GB2210605 or EP0681989 between 700° C. and 850° C. in an atmosphere containing between 0.1% and 21% O2. Heat Treatment of the pyrolysis powder under controlled conditions produces a powder with a particular phase composition, that is highly homogeneous and has a small particle size distribution, that is inherently more reactive than powders heat treated in the same way but produced using other processes.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: January 13, 2004
    Assignee: Merck Patent GmbH
    Inventors: Lee Woodall, Ru-Shi Liu, Ya-Wei Hsueh, Wolfgang Wilhelm Schmahl, Sebastian Raeth
  • Liquid-crystalline medium
    Patent number: 6677003
    Abstract: A liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, characterized in that it comprises one or more compounds of the formula I and one or more compounds of the formula IA in which are as defined herein, is suitable for use in MLC, TN and STN displays.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: January 13, 2004
    Assignee: Merck Patent Gesellschaft mit
    Inventors: Georg Lussem, Dagmar Klement, Volker Reiffenrath
  • Process for the preparation of ring compounds
    Publication number: 20040006235
    Abstract: In a process for the preparation of ring compounds via a combinatorial synthesis, the reaction procedure is based on a Suzuki coupling, subsequent halo-demetallation and finally a further Suzuki coupling. The Suzuki couplings are each carried out with a boronic acid or a boronic acid ester. The reaction procedure uses provides novel ring compounds and uses novel synthesis units used for this purpose. The novel ring compounds are suitable for use as constituents in liquid-crystalline mixtures.
    Type: Application
    Filed: March 17, 2003
    Publication date: January 8, 2004
    Applicant: Merck Patent GmbH
    Inventors: Detlef Pauluth, Peer Kirsch, Peter Baeuerle, Oliver Deeg
  • Conjugate, its preparation and use
    Patent number: 6673336
    Abstract: The invention relates to a conjugate which can be used for preparing dermatological and cosmetic compositions. The invention also relates to processes for preparing such conjugate and to its use.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: January 6, 2004
    Assignee: Merck Patent, GmbH
    Inventors: Herwig Buchholz, Eike Poetsch, Ralf Rosskopf, Ralf Anselmann, Michael Kirschbaum, Frank Pflücker
  • 5-chloro-3-(4-methanesulfonylphenyl)-6?-methyl-[2,3?]bipyridinyl in pure crystalline form and process for synthesis
    Patent number: 6673935
    Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: which is useful in the treatment of cyclooxygenase-2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising the Form V polymorph of Compound A. The invention also encompasses a process for synthesizing the Form V polymorph of Compound A.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: January 6, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Louis S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Process for the preparation of 1,2,4-triazolin-5-one derivatives
    Patent number: 6673939
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R represents hydrogen, C1-10alkyl, haloC1-10alkyl or aryl; which are useful intermediates in the preparation of morpholine derivatives of formula (A). Compounds of formula (A) are useful as therapeutic agents.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: January 6, 2004
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Cameron John Cowden
  • Combination therapy for reducing the risks associated with cardiovascular disease
    Patent number: 6673831
    Abstract: The instant invention provides methods for preventing or reducing the risk of developing atherosclerosis, as well as for halting or slowing the progression of atherosclerotic disease once it has become clinically evident, comprising the administration of a therapeutically effective amount of an HMG-CoA RI in combination with folic acid or a pharmaceutically acceptable salt or ester thereof to a person who is at risk of developing atherosclerosis or who already has atherosclerotic disease.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: January 6, 2004
    Assignee: Merck & Co., Inc.
    Inventor: Jonathan A. Tobert
  • Method of producing n-(4,5-bis-methanesulfonyl-2-methyl-benzoyl)-guanidine, the hydrochloride thereof
    Patent number: 6673968
    Abstract: The present invention relates to an NHE-1 selective Na+/H+ antiporter inhibitor N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine, hydrochloride, to its hydrochloride hydrate, and to a process for the preparation.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: January 6, 2004
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Rolf Gericke, Manfred Baumgarth, Hans Markus Bender, Bernhard Ladstetter